Table 5.

Nonexhaustive DUBs inhibitors in anti‐cancer and inflammation.

DUB	Inhibitor	Characteristics of inhibition	Disease indication
USP1	ML323	Highly selective, reversible	Oncology[ 274 ]
	SJB2‐043	Highly selective	Oncology[ 576 ]
	SJB3‐019A	Highly selective, irreversible	Oncology[ 577 ]
	GW7647	Non‐selective, reversible	Oncology[ 275 ]
	Pimozide	Non‐selective, reversible	Oncology[ 275 ]
	Rottlerin	Non‐selective, irreversible	Oncology[ 275 ]
USP2	ML364	Non‐selective, reversible	Oncology[ 578 ]
	LCAHA 6TG	Non‐selective Non‐selective, irreversible	Oncology[ 579 ] Oncology[ 580 ]
USP4	Vialinin A	Non‐selective	Inflammation and oncology[ 236 , 581 ]
USP5	WP1130 Vialinin A	Non‐selective Non‐selective	Oncology[ 296 , 582 ] Inflammation and oncology[ 236 , 581 ]
USP7	FT671 FT827 GNE‐6640 GNE‐6776 Compound 1 Compound 4 P5091 P22077 HBX41108 HBX19818 Cpd1 Cpd2 Cpd8 XL188 Ursolic acid	Highly selective Highly selective Highly selective Highly selective Non‐selective Highly selective Highly selective Non‐selective Non‐selective, irreversible Non‐selective, irreversible Highly selective Highly selective Highly selective Highly selective Non‐selective	Oncology[ 269 ] Oncology[ 269 ] Oncology[ 583 ] Oncology[ 583 ] Oncology[ 584 ] Oncology[ 585 ] Oncology, immuo‐oncology[ 584 ] Oncology, immuo‐oncology[ 586 , 587 ] Oncology[ 588 ] Oncology[ 589 ] Oncology[ 588 ] Oncology[ 588 ] Oncology[ 590 ]
USP8	DUBs‐IN‐2 MB7295	Highly selective Highly selective	Oncology[ 591 ] Oncology[ 592 ]
USP9X	WP1130 EOAI3402143	Non‐selective, reversible Non‐selective, reversible	Oncology[ 582 ] Oncology[ 404 ]
USP10	Spautin 1	Non‐selective	Inflammation[ 593 ]
USP11	MIX	Non‐selective	Oncology[ 268 ]
USP13	Spautin 1	Non‐selective	Inflammation[ 593 ]
USP14	IU‐1/analogues b‐AP15 VLX1570 WP1130 Auranofin	Non‐selective Non‐selective, reversible Non‐selective, reversible Non‐selective Non‐selective	Oncology[ 594 , 595 , 596 ] Oncology[ 597 , 598 ] Oncology[ 599 ] Oncology[ 582 ] Oncology[ 600 ]
USP15	MIX	Non‐selective	Oncology[ 268 ]
USP17	WP1130	Non‐selective	Oncology[ 582 ]
USP20	GSK2643943A	Highly selective	Oncology[ 601 ]
USP24	EOAI3402143	Non‐selective, reversible	Oncology[ 404 ]
USP25	AZ1/2/3/4	Non‐selective, reversible	Oncology[ 602 ]
USP28	AZ1/2/3/4	Non‐selective, reversible	Oncology[ 602 ]
USP30	FT385 MF094 MF095	Highly selective Highly selective Highly selective	Oncology[ 603 ] Oncology[ 603 ] Oncology[ 603 ]
USP47	Compound 1	Non‐selective	Oncology[ 584 ]
POH1	8‐thioquinoline Capzimin phen	Non‐selective Highly selective Highly selective	Oncology[ 604 ] Oncology[ 605 ] Oncology[ 606 ]
UCHL1	LDN‐57444	Highly selective	Oncology[ 607 ]
	GK13S	Highly selective	Oncology[ 608 ]
	6RK73	Highly selective, irreversible	Oncology[ 169 ]
UCHL5	IU‐1/analogues	Non‐selective	Oncology[ 594 , 595 , 596 ]
	b‐AP15 VLX1570 WP1130 Auranofin	Non‐selective, reversible Non‐selective, reversible Non‐selective Non‐selective	Oncology[ 597 , 598 ] Oncology[ 599 ] Oncology[ 582 ] Oncology[ 600 ]
Trabid	NSC112200	Highly selective	Inflammation and oncology[ 609 , 610 ]
CYLD	Subquinocin	Non‐selective	Inflammation[ 611 ]
SARS‐CoV PLpro	GRL0617	Highly selective, reversible	Anti‐infection[ 276 ]
	DDL‐701	Highly selective, reversible	Anti‐infection[ 279 ]